

Healthcare Professionals Interest in neffy: A Self-Administered Epinephrine Nasal Spray Device

Nicole M. Chase,¹ Autumn Burnette,² Daniel Soteres,³ Justin Greiwe,⁴ Harris Kaplan,⁵ Ayman Kafal⁶

¹ St. Paul Allergy & Asthma, P.A., St. Paul, MN; ² Howard University Hospital, Washington, DC; ³ University of Colorado Health Sciences Center, Denver, CO; ⁴Bernstein Allergy Group, Cincinnati, OH; ⁵Spinnaker Life Science, Boston, MA; ⁶ARS Pharmaceuticals, San Diego, CA.

RATIONALE

- Epinephrine autoinjectors (EAI) are the most common method for out-of-hospital epinephrine administration during severe allergic reactions.
- However, patients/caregivers frequently fail to dose or delay dosing, increasing the risk of complications, including hospitalization and death.
- neffy**, a small, FDA-approved, needle-free epinephrine nasal spray device, is expected to reduce dosing hesitance and increase willingness to carry and use epinephrine when needed.

METHODS

- The objectives of the study were to measure health care provider (HCP) awareness, perceptions, and prescribing of existing treatments for patients with Type 1 allergic reactions, including anaphylaxis, and to establish baseline HCP awareness and perceptions of **neffy**.
- A 20-minute web-based survey designed to assess HCP perception of current EAI as well as their interest in **neffy** was administered to 202 HCPs, including 104 allergists, 67 pediatricians, 10 primary care providers, and 21 nurse practitioner/physician assistants.
- The survey was blinded to the company sponsor.

RESULTS

- Respondents reported that the most common reasons patients failed to have or use EAI were product affordability/accessibility (66%), fear of the needle (57%), and short shelf-life (56%) (**Figure 1**).
- After being presented with **neffy**, 74% of HCPs said they would be highly likely to prescribe the product, and 83% viewed the product more favorably than current treatments, citing **neffy**'s ease of administration (90%), data showing that the product is effective (74%), and improved portability (71%) (**Figure 2**).
- Ninety-four percent of HCPs said they would be highly likely to prescribe **neffy** for patients who fear injections, and 78% said they would definitely prescribe for patients at risk of non-compliance (refusing to/not taking their EAI when needed) (**Figure 3**).

Figure 1: Importance of the Attributes in an FDA Approved, On Market-Treatment for Patients with Type 1 Allergic Reactions Including Anaphylaxis




Figure 2: Main Reasons for Prescribing neffy





Figure 3: How Likely HCPs Prescribe neffy to Each of the Following Types of Patients with Type 1 Allergic Reactions Including Anaphylaxis



CONCLUSION

- Following the introduction of **neffy**, a majority of HCPs expressed a strong willingness to prescribe it due to its ease of use, efficacy, and enhanced patient compliance.
- Healthcare providers found **neffy** favorable compared to current epinephrine auto-injectors, with 74% likely to prescribe it due to its ease of administration, effectiveness, and portability, particularly for patients fearing needles or at risk of non-compliance.

